Cancer
Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: A cohort from an integrated health care delivery system.
Fehrenbacher L, et al. J Clin Oncol. 2014 Jun 2. pii: JCO.2013.52.0858.
Fehrenbacher L, et al. J Clin Oncol. 2014 Jun 2. pii: JCO.2013.52.0858.
Study finds risk of recurrence low in smallest HER2+ breast cancer tumors,
Medical News Today, Jun 3
Exploring psychological responses to genetic testing for Lynch Syndrome within the family context
Eliezer D, et al. Psychooncology 2014 May
Eliezer D, et al. Psychooncology 2014 May
Improving referral for genetic risk assessment in ovarian cancer using an electronic medical record system
Petzel SV, et al. Int J Gynecol Cancer 2014 May
Petzel SV, et al. Int J Gynecol Cancer 2014 May
Inflammation-related genetic variations and survival in patients with advanced non–small cell lung cancer receiving first-line chemotherapy
Pu X, et al. Clinical Pharmacology & Therapeutics 2014 Jun 4
Pu X, et al. Clinical Pharmacology & Therapeutics 2014 Jun 4
Rare mutations in RINT1 predispose carriers to breast and Lynch syndrome-spectrum cancers
Park D, et al. Cancer Discovery 2014 May 2
Park D, et al. Cancer Discovery 2014 May 2
Four new genes confirmed to increase familial breast cancer risk,
EurekAlert, Jun 4
Recent BRCAPRO upgrades significantly improve calibration
Mazzola E, et al. Cancer Epidemiol Biomarkers Prev 2014 Jun
Mazzola E, et al. Cancer Epidemiol Biomarkers Prev 2014 Jun
U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations
Khozin S, et al. Oncologist 2014 May
Khozin S, et al. Oncologist 2014 May
Lynch syndrome 101 years- review- meeting summary,
[PDF 69.78 KB]
by Noralane Lindor, ASCO 2014 meeting, June 2
No hay comentarios:
Publicar un comentario